clinical trial · NCT07620574
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
CancerRenal Cell Carcinoma (RCC)Pancreatic Neuroendocrine Tumors (pNET)Extra-Pancreatic NET (epNET)Hepatocellular Carcinoma (HCC)Differentiated Thyroid Cancer (DTC)Non-Clear Cell Renal Cell Carcinoma (nccRCC)Colorectal CancerCabozantinibZanzalintinibAtezolizumabNivolumabAbirateronePrednisoneEnzalutamide
brief summary
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.
started
Jul 30, 2026
primary completion
May 31, 2030
completion
May 31, 2030
last updated
Aug 18, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol